

国内版

国际版

Rapid Remission of Refractory SAPHO Syndrome in Resp

Sign in

Q ALL

IMAGES

VIDEOS

3,580 Results

Any time

Case report: Successful treatment of refractory SAPHO ...

<https://www.researchgate.net/publication/325890340...>

Here, we report the first case of efficacious treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib. Case presentation: A 44-year-old woman presented with arthralgia in the...

Treatment for Sapho Syndrome: A Multimodality Therapy

<https://biomedres.us/fulltexts/BJSTR.MS.ID.002548.php>

Yang Q (2018) Case report: successfull treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib. Medicine (Baltimore) 97(25): e11149. Lubrano E, FM Perrotta (2017) The role of IL-17 in the treatment of psoriatic arthritis. Expert Rev Clin Immunol 13(8): 815-821. Dacoussis D (2018) Biologics in SAPHO syndrome: A systematic review.

Cited by: 1 Author: Ming Wei Tang, Shuang Liu, Chen Li, Ja...

Publish Year: 2019

[PDF] Treatment for Sapho Syndrome: A Multimodality Therapy

<https://biomedres.us/pdfs/BJSTR.MS.ID.002548.pdf>

JAK inhibitor The efficacy of JAK inhibitor tofacitinib in managing PsA has been assessed in clinical trials [22,23]. Inspired by these findings, our center tentatively treats refractory SAPHO with tofacitinib.

SAPHO syndrome

SAPHO syndrome includes a variety of inflammatory bone disorders that may be associated with skin changes. These diseases share some clinical, radiologic, and pathologic characteristics. An entity initially known as chronic recurrent multifocal osteomyelitis was first described in 1972. Subsequently, in 1978, several cases of were associated with blisters on the palms and soles. Since then, a number of associations between skin conditions and osteoarticular disorders have been reported under a variety of names, including sternocostoclavicular hyperostosis, pustulotic arthro-ostellitis, and acne-associated spondyloarthropathy. The term SAPHO was coined in 1987 to represent this spectrum of inflammatory bone disorders that may or may not be associated with dermatologic pathology.

W

Wikipedia



国内版 国际版

Rapid Remission of Refractory SAPHO Syndrome in Response to t



ALL IMAGES VIDEOS

3,660 Results Any time ▾

[Case report: Successful treatment of refractory SAPHO ...](#)

https://www.researchgate.net/publication/325890340_Case_report_Successful_treatment_of...

Here, we report the first case of efficacious treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib. Case presentation: A 44-year ...

[\[PDF\] Treatment for Sapho Syndrome: A Multimodality Therapy](#)

<https://biomedres.us/pdfs/BJSTR.MS.ID.002548.pdf>

JAK inhibitor The efficacy of **JAK inhibitor tofacitinib** in managing PsA has been assessed in clinical trials [22,23]. Inspired by these findings, our center tentatively treats **refractory SAPHO** with **tofacitinib**. Responses in clinical symptoms, inflammatory parameters and magnetic resonance imaging all demonstrated amelioration [24].

Cited by: 1 **Author:** Ming Wei Tang, Shuang Liu, Chen Li, Ja...
Publish Year: 2019

[The off-label uses profile of tofacitinib in systemic ...](#)

<https://www.sciencedirect.com/science/article/pii/S1567576920302460>

Jun 01, 2020 · Vleugels et al. reported a case series of three patients with multidrug-resistant refractory DM (one with ADM) had marked improvement in cutaneous dermatomyositis disease area and severity index (CDASI) after treated with tofacitinib, with a mean improvement of **12 points within 4 weeks (4-to 5- point change reflects a clinically significant response)** . Two ...

Cited by: 2 **Author:** Zichu Zhao, Cong Ye, Lingli Dong
Publish Year: 2020

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 52614

Manuscript Type: CASE REPORT

Rapid remission of refractory SAPHO syndrome in response to the janus kinase inhibitor tofacitinib: A case report

Ben Li, Guanwu Li, Luan Xue, Yueying Chen

Abstract

BACKGROUND

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare autoinflammatory disease for which clinical treatment has not been standardized. Janus kinase (JAK) inhibitors represent a novel therapeutic option for rheumatoid arthritis, psoriatic arthritis and some other autoinflammatory diseases. However, the clinical utility of JAK inhibitors in treating SAPHO syndrome has not been thoroughly investigated. In the present study, we describe a patient with SAPHO syndrome who

Match Overview

1	Internet 149 words crawled on 06-Mar-2020 journals.lww.com	5%
2	Internet 47 words crawled on 15-Feb-2020 Rpublishing.blob.core.windows.net	2%
3	Internet 34 words crawled on 25-Feb-2019 link.springer.com	1%
4	Internet 30 words www.zora.uzh.ch	1%
5	Crossref 26 words A.R. Webb, "Assessing benefits and risks of holiday sun exposure in children", <i>British Journal of Dermatology</i> , 2018	1%
6	Crossref 19 words C. Agusti, "Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patient"	1%
7	Internet 19 words www.ncbi.nlm.nih.gov	1%
8	Crossref 14 words Haley B. Naik, Amanda K. Ombrello, Edward W. Cowen, chapter 40 Autoinflammatory Diseases", <i>Springer Science a</i>	<1%



国内版

国际版

Rapid remission of refractory synovitis, acne, pustulosis, hyperost



ALL

IMAGES

VIDEOS

1,130 Results

Any time ▾

Efficacy of tofacitinib in synovitis, acne, pustulosis ...

<https://ard.bmj.com/content/79/9/1255> ▾

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a chronic inflammatory disease that severely affects patients' quality of life. Therapies including tumour necrosis factor inhibitors (TNFi) and bisphosphonates (BPs) yield variable efficacy.¹ **Tofacitinib**, a **Janus kinase inhibitor**, may suppress osteoclast-mediated joint damage by inhibiting the ...

[PDF] Efficacy of tofacitinib in synovitis, acne, pustulosis ...

<https://ard.bmj.com/content/annrheumdis/early/2020/04/24/annrheumdis-2020-217250.full.pdf>

Apr 24, 2020 · **Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome** is a chronic inflammatory disease that severely affects patients' quality of life. Therapies including tumour necrosis factor inhibitors (TNFi) and bisphosphonates (BPs) yield variable efficacy.¹ **Tofacitinib**, a **Janus kinase inhibitor**, may suppress osteoclast-mediated ...

Cited by: 2

Author: Yueting Li, Jianwei Huo, Yihan Cao, Mei...

Publish Year: 2020

(PDF) Case report: Successful treatment of refractory ...

https://www.researchgate.net/publication/325890340_Case_report_Successful_treatment_of...

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare inflammatory disorder with unknown etiology, while the evidence of ...

Chen Li's research works | Peking Union Medical College ...

https://www.researchgate.net/scientific-contributions/2100989791_Chen_Li

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare inflammatory disorder with unknown etiology, while the evidence of ...

Posters - 2019 - International Journal of Rheumatic ...